EUCTR2014-001374-34-DE进行中（未招募）不适用
A monocentric, observer-blind, randomized clinical study using an abrasive wound model with an intra-individual comparison to investigate the wound healing properties of a topical wound healing product in comparison to untreated and a reference product in 36 healthy subjects
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Men and women
- •Age 18 to 55
- •Skin type I to III (according to Fitzpatrick et al., 1974)
- •Willingness to actively participate in the study and to come to the scheduled visits
- •Willingness to discontinue the application of leave-on cosmetics (e.g. creams, lotions) and to avoid the use of detergents (e.g. soaps) in the test area throughout the course of the study and 3 days before the start of study
- •Willingness to avoid hard physical exercises (with heavy sweating), sauna, swimming and bathing during the test phase
- •Willingness to avoid extensive artificial as well as natural UV light on the test areas during the whole course of the study and for at least 3 months after the end of study
- •Willingness to avoid contact of the test area with water during the time of patch application (careful showering)
- •Uniform skin color and no erythema or dark pigmentation in the test area
- •Signed written informed consent to participate in the study
- •Negative urine pregnancy test (in female subjects of child bearing potential)
- •Reliable methods of contraception which result in a low failure rate (i.e. less than 1% per year) for women of childbearing potential (implants, injectables, combined oral contraceptives, some intrauterine-devices, sexual abstinence or vasectomised partner)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 36
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Active skin disease, moles, tattoos, strong pigmentation and hairy skin at the test area or scars in the test area that would influence the visual scoring
- •Psoriasis and/or Lichen ruber and/or atopic dermatitis
- •History of keloids and hypertrophic scars
- •History of plaster sensitivity
- •Intake of drugs interfering with the immune system (e.g. antiphlogistics, corticosteroids, immuno-suppressants, and antihistamines) within up to 30 days (depending on the kind of therapy) before the start of the study as well as during the study
- •Concomitant therapy with substances at doses affecting blood coagulation (e.g. acetylic acid, anticoagulants diuretics, thiazides) within up to 14 days prior to the start of the study as well as during the study
- •Topical treatment of the test areas with drugs (e.g. with corticosteroids, antibiotics, anti-inflammatory substances) within 14 days prior to the start of the study as well as during the study ( moisturizers and sun protection are allowed until 3 days prior)
- •Treatment (within up to 14 days prior to the start of the study as well as during the study) with medication of concomitant illnesses which might influence the study (e.g. diabetes, dysfunction of blood clotting)
- •Intensive UV-light exposure within two weeks before the start of the study as well as during the study at the test areas
- •Removal of axillary lymph nodes
- •Allergy to the ingredients of the test products
- •Pregnancy or lactation
- •Severe illness on account of which the subject should not participate in the study in the opinion of the investigator
- •Psychiatric conditions that might limit the participation in the trial and/or that lead to the assumption that the ability to completely understand the consequences of consent is missing
- •Any history of drug addiction or alcoholism in the past 3 years
- •Infectious diseases
- •Subjects with expected poor compliance
- •If in the opinion of the investigator the subject should not participate in the study for any reason
- •Participation in a clinical trial within the last 30 days prior to the start of this study and during the study conduct
- •Employees of the study sites or of the Sponsor company
- •Subjects who are inmates in psychiatric wards, prison or state institutions
- •Subjects underlying any other restrictions due to the participation in other tests / test institutes
研究者
相似试验
招募中
1 期
A prospective, observer-blind, randomized clinical trial to investigate and compare the clinical efficacy of Chloroprocaine 3% gel and Oxybuprocaine 0.4% eye drops anesthesia for clinical practice in pediatric population.male/female outpatients, aged 0-17 years scheduled to undergo ocular exams with a need of ocular surface anesthesia.CTIS2023-504477-21-01Sintetica S.A.74
进行中（未招募）
1 期
A prospective, observer-blind, randomized clinical trial to investigate and compare the clinical efficacy of Chloroprocaine 3% gel and Oxybuprocaine 0.4% eye drops anesthesia for clinical practice in pediatric population.male/female outpatients, aged 0-17 years scheduled to undergo ocular exams with a need of ocular surface anesthesia.CTIS2023-504477-21-00Sintetica S.A.74
已完成
不适用
The therapeutic effect of platelet enriched blood plasma for treating knee osteoarthritisCTRI/2018/03/012293Department Of Orthopaedics SVRR Government General Hospital Tirupati100
尚未招募
4 期
A Randomized, Single-blind, Multi-center Clinical Study for Artemisinin-Piperazine and Artemether-Benzolol in the Treatment of Uncomplicated Falciparum MalariaMalariaITMCTR1900002588Guangzhou University of Chinese Medicine
尚未招募
不适用
A study comparing 2 drugs in reversal of general anaesthesiaCTRI/2023/10/058419SIMS hospitals, Department of anaesthesiology and pain management